98%
921
2 minutes
20
This review outlines the progress and challenges in HIV cure research, with a particular focus on gene therapy, latency-reversing agents (LRAs), immunotherapy, and stem cell transplants. The objective of these advances is to achieve either a sterilizing or a functional cure, whereby the virus is either eradicated or controlled without the need for ongoing treatment. Gene editing tools, such as CRISPR-Cas9, have demonstrated the potential to remove HIV DNA from cells. LRAs, on the other hand, aim to reactivate latent virus, thereby rendering it susceptible to treatment or immune clearance. Immunotherapy, including therapeutic vaccines and broadly neutralizing antibodies, aims to enhance the immune response to HIV. However, achieving long-term suppression without antiretroviral therapy remains a significant challenge. Stem cell transplants have resulted in instances of remission; however, the methodology is intricate, perilous, and viable solely for patients with particular medical requirements. Each approach encounters challenges pertaining to safety, administration, and accessibility. In sum, while considerable advancement has been achieved, a combination of therapeutic strategies and further innovations are imperative for the development of a sustainable, widely accessible HIV cure.
Download full-text PDF |
Source |
---|
JAC Antimicrob Resist
October 2025
Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.
Background: is a cause of sexually transmitted infections (STIs). This study assessed its prevalence, resistance and coinfection with / infections in MSM with HIV.
Methods: MSM in HIV care in Hong Kong were recruited during 2023-24 for completion of an online survey, and self-collection of urine specimens, rectal and pharyngeal swabs, which were tested for .
J Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFLancet Reg Health West Pac
August 2025
Global HIV, Hepatitis and STI Programmes, World Health Organization (WHO), Geneva, Switzerland.
Background: The global spread of antimicrobial resistance (AMR) in threatens empiric single-dose gonorrhoea treatment. Enhanced global AMR surveillance is imperative. We report i) gonococcal antimicrobial susceptibility and resistance data from 2023 in the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (WHO EGASP) in the WHO Western Pacific Region (Cambodia, the Philippines, Viet Nam), Southeast Asian Region (Indonesia, Thailand), and African Region (Malawi, South Africa, Uganda, Zimbabwe), and ii) metadata of the gonorrhoea patients.
View Article and Find Full Text PDFJ Med Virol
September 2025
Laboratory of Dermatology and Immunodeficiencies, Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.
Mother-to-child transmission (MTCT) is the primary route of human T-lymphotropic virus type 1 (HTLV-1) infection. Although formula feeding reduces breastfeeding-associated transmission, MTCT still occurs, implicating pregnancy or delivery as key transmission windows. In this study, placental tissues from nine HTLV-1-positive mothers were analyzed using DNA/RNAscope, revealing low HTLV-1 DNA and RNA levels and a low RNA/DNA ratio, consistent with latent infection in the placenta and potentially explaining the low MTCT rate.
View Article and Find Full Text PDFbioRxiv
August 2025
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
The vast majority of persons living with HIV-1 who discontinue antiretroviral therapy (ART) demonstrate viral rebound, but the tissue-level events that lead to rebound viremia are poorly understood. Here we report the origin, dynamics, and correlates of viral rebound in 16 rhesus macaques (RMs) infected with molecularly barcoded SIVmac239M, treated with ART for 70 weeks, and necropsied on day 12 after ART discontinuation. Barcode analysis of plasma following ART discontinuation identified 1 to 38 rebounding barcode-defined viral lineages per animal, with 1 to 4 rebounding lineages contributing to first measurable rebound viremia.
View Article and Find Full Text PDF